Acrivon Therapeutics, Inc. Common Stock (ACRV) Investor Relations Documents

Acrivon Therapeutics, Inc. Common Stock (ACRV) investor relations documents from the company's IR site: 1 presentation, 25 press releases; latest deck 2026-08-12. Read in-app with summaries. First-party data.

Corporate Presentation – August 2026: Acrivon Therapeutics' August 2026 presentation details its AP3 AI-driven proteomics platform for precision medicine, with ACR-368 in Phase 2b/3 for endometrial cancer and ACR-2316

Investor relations documents — source: company IR site

Published	Type	Document
2026-08-12	Presentation	Corporate Presentation – August 2026
2026-08-12	Press release	PDF Version
2026-08-12	Press release	Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts
2026-08-05	Press release	Acrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoi
2026-07-21	Press release	Acrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Or
2026-05-21	Press release	Acrivon Therapeutics to Present at TD Cowen’s 7th Annual Oncology Innovation Summit
2026-05-15	Press release	Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-05-13	Press release	Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts
2026-04-17	Press release	Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies wit
2026-04-15	Press release	Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-03-19	Press release	Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
2026-03-17	Press release	Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-36
2026-02-24	Press release	Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
2026-02-23	Press release	Key Opinion Leader (KOL) Panel to Discuss Acrivon’s ACR-368 Endometrial Cancer (EC) Trial during the 2026 European Socie
2026-01-23	Press release	Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (E
2026-01-08	Press release	Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerat
2026-01-06	Press release	Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial
2025-03-27	Press release	Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results
2024-11-13	Press release	Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
2024-08-13	Press release	Acrivon Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
2024-05-14	Press release	Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
2024-03-28	Press release	Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
2023-11-09	Press release	Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
2023-08-11	Press release	Acrivon Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
2023-05-09	Press release	Acrivon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
2023-03-28	Press release	Acrivon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

ACRV overview · ACRV earnings · ACRV financials · ACRV KPIs · ACRV ownership · ACRV peers · ACRV filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.